Form 8-K - Current report:
SEC Accession No. 0001213900-24-093531
Filing Date
2024-11-01
Accepted
2024-11-01 16:23:48
Documents
15
Period of Report
2024-10-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0219289-8k_inmune.htm   iXBRL 8-K 24650
2 PRESS RELEASE OF INMUNE BIO INC., DATED OCTOBER 31, 2024 ea021928902ex99-1_inmune.htm EX-99.1 100966
3 GRAPHIC ex99-1_001.jpg GRAPHIC 4597
  Complete submission text file 0001213900-24-093531.txt   322090

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE inmb-20241031.xsd EX-101.SCH 3018
5 XBRL LABEL FILE inmb-20241031_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE inmb-20241031_pre.xml EX-101.PRE 22361
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0219289-8k_inmune_htm.xml XML 3792
Mailing Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432
Business Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432 8589643720
Inmune Bio, Inc. (Filer) CIK: 0001711754 (see all company filings)

EIN.: 475205835 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38793 | Film No.: 241419385
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)